Amgen and co-collaborator Allergan released positive data from its second late-stage trial assessing their biosimilar candidate, ABP 798, in comparison to Roche's Rituxan, or rituximab, as a treatment for CD20-positive B-cell non-Hodgkin lymphoma. Results indicated the two drugs were comparable in terms of clinical equivalence, safety and immunogenicity.
Amgen, Allergan tout positive results from Rituxan biosimilar trial
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.